Cancer Research Current Affairs - 2019

Category Wise PDF Compilations available at This Link

India and UK sign MoU for collaboration in cancer research       

India and United Kingdom have signed Memorandum of Understanding (MoU) for collaboration in cancer research.    It is follow-up to joint statement issued by Prime Ministers of India and UK during visit of PM Narendra Modi to the UK in April 2018.

Key Facts

The MoU was signed between Department of Biotechnology (DBT) and Cancer Research UK (CRUK) for India-UK Cancer Research Initiative for collaboration in cancer research for the next five years. Under it, both CRUK and DBT will invest 5 million pounds each in this five-year pilot project and seek further investment from other potential funding partners.

India-UK Cancer Research Initiative will identify core set of research challenges that address issues of affordability, prevention and care of cancer patients by bringing together leading Indian and UK experts in clinical research, demographic research, new technologies and physical sciences.

The initiative will provide funding to develop new research alliances and undertake impactful research to enable significant progress against cancer outcomes. It will also provide catalysing platform for scientists and researchers in India and UK to co-create solutions for affordable cancer care that improve cancer outcomes around the globe.

Month: Categories: National


Novel drug compound inhibiting skin cancer discovered: NCCS Study

Researchers from the Pune-based National Centre for Cell Science (NCCS) have successfully isolated cancer stem cells that cause skin cancer.

They have successfully demonstrated that Andrographolide (a compound) isolated and purified from Andrographis paniculata (a herb) found in India is effective in inhibiting tumour growth both in skin cancer and lung metastasis in mice.

How did they undertake research?

  • In order to establish that CD133 positive cancer stem cells cause cancer, the researchers had injected these cells subcutaneously into mice.
  • The CD133 positive cancer stem cells that develops tumour faster than non-cancer stem cells.
  • It also produces lung metastasis in a different set of mice that received the cells through intravenous injection.
  • The research showed that all the animals injected with CD133 positive cancer stem cells developed skin cancer (melanoma).
  • When the compound Andrographolide was injected in the mice, it inhibiting tumour growth both in skin cancer and lung metastasis.

Significance of Research

  • The study indicates that the compound Andrographolide has therapeutic potential for the management of cancer stem-cell mediated melanoma growth and lung metastasis.
  • The compound has ability to inhibit CD133 positive cancer stem cells growth which mediates tumour growth and lung metastasis.
  • It also shows enhanced ability to flush out cancer drugs from inside the cells thereby increasing the probability of tumour relapse.

Month: Categories: Science & Technology